Published in final edited form as:

Postdoc J. 2015 June ; 3(6): 71–87.

PI3King the right partner: unique interactions and signaling by p110 β

Hashem A. Dbouk

Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390

Abstract

Phosphoinositide 3-kinases (PI3Ks) are central regulators of cellular responses to extracellular stimuli, and are involved in growth, proliferation, migration, and metabolism. The Class I PI3Ks are activated by Receptor Tyrosine Kinases (RTKs) or G Protein-Coupled Receptors (GPCRs), and their signaling is commonly deregulated in disease conditions. Among the class I PI3Ks, the p110 β isoform is unique in being activated by both RTKs and GPCRs, and its ability to bind Rho-GTPases and Rab5. Recent studies have characterized these p110 β interacting partners, defining the binding mechanisms and regulation, and thus provide insight into the function of this kinase in physiology and disease. This review summarizes the developments in p110 β research, focusing on the interacting partners and their role in p110 β -mediated signaling.

PI3Ks are a family of lipid kinases that are central in cellular signaling, mediating responses to growth factors and extracellular stimuli, as well as regulating a wide variety of intracellular processes [1, 2]. PI3Ks are divided into 3 classes based on sequence homology between catalytic subunits and substrate specificity (Table 1) [3, 4]. The class I PI3Ks is further subdivided into two subclasses based on their regulatory subunits, with class IA consisting of three catalytic subunits (p110 α , β , and δ) which associate as obligate heterodimers with one of five different regulatory subunits (p85 α , p55 α , p50 α , p85 β , and p55 γ) collectively referred to as p85 [5, 6], while the class IB consists of a single catalytic subunit, p110 γ , that can associate with either of two regulatory subunits, p87 and p101, which can mediate different signaling inputs [2, 7–9]. The class I PI3Ks use PI(4,5)P₂ as a substrate to generate the product PI(3,4,5)P₃ which initiates major signaling pathways downstream [1]. While the sequence, domain composition, and structures of the class I PI3K catalytic isoform are to a large extent similar and homologous, the main differences in function amount from tissue-specific distribution of the catalytic subunits, as well as an array of common and unique interacting partners that modulate intracellular distribution, responses and functions of the isoforms. The identification of these interacting partners and characterization of their effects on different catalytic subunits is paramount for our understanding of these enzymes and our ability to target their unique and overlapping functions.

The signaling downstream of PI3Ks and the generation of PI(3,4,5)P₃ is mediated through the recruitment of Pleckstrin homology (PH)-domain containing proteins which can bind to PI(3,4,5)P₃ [10, 11]. Among PH-containing proteins, Akt, which was first discovered as the cellular homolog of the transforming retroviral oncogene v-Akt [12, 13], represents the canonical signaling pathway downstream of PI3Ks [14]. Akt is recruited to the membrane by its PH domain following PI3K activation where it is activated by phosphorylation on two residues: T308 in the kinase domain is phosphorylated by another PH-containing protein, phosphoinositide-dependent kinase 1 (PDK1) [15], and S473 in the hydrophobic motif which is phosphorylated by the mammalian target of Rapamycin complex 2 (mTORC2) [16]. Akt has multiple downstream substrates with a common consensus motif for phosphorylation [17], and can lead to regulation of various pathways, most prominently activation of mTORC1 via phosphorylation and inhibition of Tuberous Sclerosis Complex 2 (TSC2) which, together with TSC1, form a GTPase-activating protein (GAP) complex for Ras homolog enriched in brain (Rheb) [18–20]. Rheb can position the mTORC1 at the late endosome/lysosome where it is active [21], and therefore release of TSC1/2-mediated inhibition of Rheb by Akt results in activation of the mTORC1 pathway. In turn, mTORC1 modulates ribosomal biogenesis, protein translation, and increased cell size and growth through multiple targets, including ribosomal p70 S6 kinase and the eIF4E binding proteins (4E-BP 1 and 2) [22]. Other Akt targets include Glycogen Synthase Kinase 3 (GSK3) which is inhibited by Akt phosphorylation [23], Akt Substrate of 160 kDa (AS160) whose phosphorylation by Akt allows the membrane translocation of the insulin-dependent glucose transporter 4 (GLUT4) [24, 25], the pro-apoptotic Bcl2-antagonist of cell death (BAD) leading to decreased cell death [26], Forkhead Box O (FOXO) transcription factors leading to 14-3-3 binding and cytosolic sequestration to prevent their transcription of pro-apoptotic genes [27, 28], as well as modulation of Nuclear Factor Kappa B (NFκB) function and activity through various mechanisms [29–31]. The net outcome of class I PI3K pathway activation is the induction of cell growth and proliferation, coupled to inhibition of apoptosis, and thus this pathway is of great importance in development and is commonly hijacked in cancer and other diseases.

The division of class I PI3Ks into two subclasses was for a long time in conjunction with their responses to distinct signaling inputs: While both subclasses were generally shown to signal downstream of Ras [32], the class IA catalytic subunits with the SH2-domain containing p85 regulatory subunits signal downstream of RTKs, while the class IB subunit p110γ/p101 can bind to Gβγ subunits and signal downstream of GPCRs [2]. However, recent data has increased the complexity of the signaling by both subclasses, with the class IA p110β subunit shown to be activated by GPCRs [33–37] and p110γ being activated following RTK and Toll-like receptor stimulation in myeloid cells [38]. In addition, recent data has shown the ability of p110β to interact with Rab5 [39, 40] as well as with small GTPases Rac and cdc42 but not with Ras [41], suggesting that this isoform is unique among class I PI3Ks in terms of its interactions and regulation. Interestingly, among the PI3Ks, while p110α knockout causes mid-gestational embryonic lethality [42] and p110δ or p110γ knockout mice are viable [43, 44], p110β knockout causes lethality by embryonic day 3.5 [45], a very early time point highlighting the extreme significance of p110β and the major

roles it plays in development, thereby necessitating further study and understanding of this isoform.

Disruption of PI3K signaling is a hallmark of many diseases, in particular cancer [46], where a large number of mutations in the pathway have been observed, with major mutational hotspots in p110 α and p85 [47–49], while the Phosphatase and Tensin Homolog deleted from chromosome 10 (PTEN), which antagonizes PI3K signaling and dephosphorylates PI(3,4,5)P₃ back to PI(4,5)P₂, is commonly mutated or deleted in tumors [50, 51]. Interestingly, mutations in other class I catalytic subunits are rare [52, 53], with only one p110 β mutation having been described and characterized [53], while some amplifications of p110 β and p110 δ have been documented [54, 55]. The reason behind the accumulation of oncogenic mutations in the p110 α subunit and not other class I catalytic isoforms is because, at least *in vitro*, p110 α is only transforming when mutated while the other subunits are all transforming when over-expressed in the wild-type state [56]. A major recent finding was the requirement of p110 β as the driving PI3K subunit in PTEN-null driven prostate tumors [57], although this is not a general case for all PTEN-deficient cancers as another study suggested that the specific catalytic subunit driving PTEN-null tumors may also be dependent on the tissue of origin of the tumor [58]. Furthermore, p110 β signaling has been implicated in the pathogenesis of other tumors such as ErbB2-driven or H-Ras driven tumors [59, 60]. In addition, p110 β has been implicated in a variety of other diseases and physiological processes including male fertility, thrombosis, metabolism, lung fibrosis, and Fragile X-syndrome [41, 59–65]. These studies have increased the interest in p110 β and necessitated the understanding of p110 β regulation by interacting partners and characterizing its many functions.

p110 β interactions and their impact on p110 β regulation

p110 α and p110 β are both ubiquitously expressed [66, 67], and yet display major differences in their modes of regulation and their signaling, particularly as seen by the ability of wild-type p110 β to transform cells while p110 α does not [56]. p110 β is distinct among the class I PI3Ks in the diversity of its interacting partners (Fig. 1), and these allow multiple signaling inputs to control the activity, localization, and signaling of p110 β in cells. In addition to different interacting partners, p110 β displays unique contacts with the p85 subunit, which is a common regulator of all class IA subunits, while it does not interact with Ras, which is an activator of all other class I PI3Ks. The presence of unique interactions as well as the lack or divergence in mechanisms of interactions shared with other PI3K catalytic subunits make the understanding of p110 β interactions crucial for deciphering its regulation and many functions, and how these can be disrupted in disease conditions.

p110 β regulation by the p85 regulatory subunits

The class IA PI3K catalytic subunits are obligate heterodimers with p85 regulatory subunits [5], requiring this interaction for thermal stability of the p110 subunit [68]. Furthermore, p85 binding to p110 subunits results in inhibition of the basal activity of p110s and allows their activation following RTK stimulation via recruitment to activated receptors through the two SH2 domains within p85 [68–71]. The p85 subunit was shown to form multiple contacts with the p110 α subunit, with the inter-SH2 (iSH2) coiled coil making contacts with the

Adaptor Binding Domain (ABD) and the C2 domain of p110 α , while the N-terminal SH2 domain (nSH2) formed contacts with the C2, helical, and kinase domains of p110 α [48, 69, 72–75]. The interaction with the ABD is essential for the stabilization of the p110 molecule, whereas the other contacts have been shown to mediate the inhibition of basal activity and regulate the activation by phosphopeptides.

Consistent with the importance of these p85-p110 contacts in regulation of activity and signaling by class IA PI3Ks, these contact sites between the C2, helical or kinase domains of p110 α and the iSH2 and nSH2 of p85 are hotspots for oncogenic mutations [47, 48, 69]. Interestingly, mutations in p85 subunits have been suggested to work mainly through p110 α , not p110 β [76, 77]. Analysis of the p85-p110 β contact residues suggested a possible mechanism for the p110 β -independent mechanism of p85 mutations: A contact residue mediating the p110 C2-p85 iSH2 contact and inhibition in p110 α is not conserved in p110 β . Rather, the analogous residue in p110 β is similar to an oncogenic p110 α mutation, leading to disruption of the C2-iSH2 contact between p110 β and p85, and subsequently decreased inhibition of p110 β basal activity [77, 78]. This is supported by Hydrogen-Deuterium exchange data showing that the C2-iSH2 interface between p110 β and p85 is more exposed and dynamic compared to that of p110 α or p110 δ , consistent with decreased inhibition of p110 β at that interface [79]. This diminished inhibitory contact between the C2 and iSH2 domains would lead to a higher basal activity in p110 β . The importance of p110 β basal activity is further suggested by studies in PC-3 cells, which are PTEN null prostate cancer cells, showing that basal PI(3,4,5)P₃ level in cells is p110 β -dependent [80]. The connection between p110 β basal activity and PTEN-deficient tumors is more intriguing due to the presence of PTEN in a complex with p85 and p110 β [81]. This provides a model for the requirement of p110 β in PTEN $^{-/-}$ tumors whereby p85-p110 β -PTEN complex normally maintains the low threshold of PI(3,4,5)P₃ levels in cells through a constant cycle of high p110 β basal activity countered by the associated PTEN, and this delicate balance is disrupted in tumors driven by loss of PTEN function [78].

In contrast to the loss of an inhibitory interface between p110 β and p85 at the C2-iSH2 contact region, crystallization of p110 β with the icSH2 domains of p85 revealed surprising new inhibitory contacts between the kinase domain of p110 β and the C-terminal SH2 domain (cSH2) of p85 [82, 83]. Unlike the inhibitory interaction between the nSH2 domain and the helical domain which maintains the phosphopeptide binding region of the SH2 covered, the cSH2-kinase domain contacts do not block the phosphopeptide binding region. The mechanism of release of inhibition requires a longer peptide following the phosphotyrosine residue, compared to the nSH2, and such a longer peptide can disrupt the inhibitory contacts between the cSH2 and kinase domain. This allows for the possibility to target the cSH2 to block the binding of phosphotyrosine-containing peptides without affecting the inhibitory contacts with the kinase domain [84], paving the way for peptide-mimetics to specifically block cSH2-mediated activation of p110 kinases.

p110 β interaction with Rac and cdc42

The assumption that all class I PI3Ks are activated similarly by Ras [8, 85–90] was recently shattered by a study carefully looking at the interaction of p110 β and Ras-GTP but found no

regulation of that catalytic subunit by Ras [41]. Instead, the work by Hirsch and colleagues revealed novel interactions of the p110 β RBD domain with Rac1 and cdc42, and to a much weaker level with RhoA and RhoG [41]. The interactions of Rac and cdc42 with p110 β can directly stimulate the kinase activity of p110 β , but more importantly can also regulate the activation of p110 β downstream of GPCRs, via the Rac-GEF DOCK180/ELMO1-mediated pathway [41, 91]. According to the model, p110 β can directly bind to G $\beta\gamma$ subunits and get activated to near maximal level, while simultaneously DOCK180/Elmo1 are recruited by direct binding to G $\beta\gamma$ subunits as well, activating Rac and placing in close proximity to p110 β , whereby Rac interaction with p110 β leads to full activation of p110 β downstream of GPCRs [41, 92]. This interaction with Rac was shown to be important for LPA-mediated fibroblast chemotaxis *in vitro* and in an *in vivo* model of lung fibrosis [41], and thus targeting this specific interaction could have important benefits in some inflammatory syndromes or other GPCR-mediated diseases [93–95]. The extent of the contribution of Rac/cdc42 interaction with p110 β to the overall response to GPCR stimulation is still not clearly defined relative to the effect of direct G $\beta\gamma$ binding, in particular whether these events occur concurrently or are spatially and/or temporally segregated with respect to the overall p110 β response to GPCRs.

p110 β activation by G $\beta\gamma$ subunits downstream of GPCRs

As mentioned in the section above, there are two mechanisms or steps for p110 β activation downstream of GPCRs: 1) The major mechanism for p110 β activation following GPCR stimulation is direct binding of p110 β to G $\beta\gamma$ subunits, accounting for the majority of the p110 β activity; 2) The second mechanism which adds to the G $\beta\gamma$ -mediated stimulation to reach maximal p110 β activity is via the DOCK180/Elmo1-Rac mediated pathway. The direct activation of p110 β downstream of GPCRs and interaction with G $\beta\gamma$ subunits was first shown more than a decade ago [33–35] and later shown to be the major pathway activating p110 β , whereas overall RTK-stimulated PI3K activity was unaltered upon loss or inhibition of p110 β [36, 59, 60].

Unlike characterization of p110-p85 interactions, defining the p110 β -G $\beta\gamma$ interaction was more difficult due to the transient nature of the interaction and the lack of a unique motif amongst G $\beta\gamma$ interacting proteins. A dual approach to identify the p110 β -G $\beta\gamma$ interaction interface using sequence alignments between class IA p110 subunits and hydrogen-deuterium exchange mass spectrometry (HDX-MS) identified the linker loop between the C2 and helical domains (C2-helical linker) as the region required for interaction with G $\beta\gamma$ subunits [37]. Further sequence alignment to define conserved p110 β residues in this C2-helical linker identified two Lysine (KK) at residues 532-533 as central in this interaction [37], and analogous residues within p110 γ were later shown to be required for the interaction with G $\beta\gamma$ subunits [96]. The interaction with G $\beta\gamma$ was shown to affect p110 β in both kinase-dependent and kinase-independent mechanisms, with the localization of p110 β to plasma membrane playing an important role in G $\beta\gamma$ -mediated functions of p110 [37]. These data point towards a scaffolding function of p110 β that is still uncharacterized and could have a significant role on signaling independent of the lipid kinase activity. Interestingly, the HDX-MS study also revealed a novel interface on the G $\beta\gamma$ subunit for interaction with effector proteins. The interaction with p110 β was shown to involve both the

classical interface that coincided with the region of interaction of many other G $\beta\gamma$ effectors as well as novel interface that was unique to p110 β [37]. This provides a mechanism to target the p110 β -G $\beta\gamma$ interface specifically, without altering the interaction of G $\beta\gamma$ subunits with other proteins, and preliminary analyses suggested the feasibility of such an approach [37].

The importance of the G $\beta\gamma$ interaction and the function of p110 β downstream of GPCRs is highlighted by studies showing the impact of blocking both G $\beta\gamma$ -mediated direct activation and the DOCK180/Elmo1-Rac-mediated complementary activation of p110 β on disease [37, 41]. Mutation of the residues required for p110 β -G $\beta\gamma$ interaction decreased invasion towards GPCR ligands in different cell lines and also decreased migration of tumor cells specifically lacking PTEN [37]. This is consistent with a requirement for p110 β in PTEN-deficient tumors [57], and suggests that the input of GPCRs to p110 β is of central importance in the development and progression of these tumors. The ability to target the p110 β -G $\beta\gamma$ interface with minimal side effects and cross-reactivity with other PI3K isoforms or G $\beta\gamma$ effectors could prove highly beneficial for the treatment of many tumors dependent on this pathway.

p110 β interaction with Rab5

p110 β has been shown to bind to Rab5-GTP, possibly on clathrin-coated vesicles, [39, 97], and was suggested by yeast two-hybrid to bind via two sections of p110 β : a part of the ABD-RBD linker and RBD domain (residues 136-270) and a section of the helical and kinase domains (residues 658-759) [39]. This interaction of p110 β with Rab5 has no effect on the kinase activity of p110 β [41]. To accurately identify the residues of p110 β required for Rab5 interaction, Backer and colleagues performed sequence analysis coupled with analysis of the crystal structure of p110 β [82] to identify potential interaction sites, and subsequently identified two residues (Q596 and I597) in the helical domain as necessary and sufficient for interaction with Rab5 [98].

This interaction with Rab5, which has well-studied roles in endocytosis and early-endosomal maturation via interaction with the class III PI3K vps34 [99, 100], supported evidence for a possible kinase-independent role of p110 β in endocytosis and trafficking [59, 60]. The p110 β mouse knockout studies showed a defect in clathrin-mediated endocytosis, with decreased EGF and transferrin uptake, as well as decreased clathrin staining beneath the plasma membrane without change in the perinuclear clathrin levels, and a surprising complete loss of EEA1 staining, all of which can be rescued with the expression of kinase-dead p110 β at physiological levels [59, 60]. The role of p110 β in endocytosis has not been further characterized, and requires more studies to analyze the exact mechanism of any potential role for p110 β in this process, as well as define the timing or stage of this process in which p110 β is required.

Interestingly, a recent study identified p110 β as a positive regulator of autophagy, a function which was mediated through association with the vps34/vps15-Beclin-1 Atg14L complex [101]. The interaction of p110 β with the vps34 complex suggested a potential link through Rab5, and this was confirmed using point mutants of p110 β that abrogated Rab5 binding to show a requirement for the interaction in autophagy [40]. The role of p110 β in autophagy was shown to be downstream of growth factor limitation and not nutrient deprivation. The

mechanism of action of p110 β under growth factor-poor conditions is through the increase of Rab5-GTP levels by protecting the Rab5-GTP from the Rab-GAP activity of p85 [40, 102]. In turn, the increased Rab5-GTP can increase vps34 activity and drive autophagy. In contrast, under growth factor-replete conditions, p110 β is recruited away from Rab5 to the plasma membranes and receptors, leaving Rab5 to be mostly in the GDP-bound state due to the Rab-GAP activity of p85, which leads to low levels of autophagy [40].

The p110 β -Rab5 interaction has defined roles in autophagy, but its impact on endocytosis or the activation kinetics of p110 β has not been studied. The interaction with Rab5 could recruit p110 β to early endosomes, from which signaling could still occur. A similar situation has been shown for p110 γ which is activated by G $\beta\gamma$ subunits at Rab11a-positive endosomes, and this is required for proper Akt signaling [103]. One point to highlight is the relative proximity in the p110 β crystal structure of the G $\beta\gamma$ and the Rab5 binding interfaces, opening the possibility for the interactions being cooperative or mutually exclusive, or even provide a model for a spatial and temporal regulation of the interactions to control the time course of p110 β stimulation, activity, and localization. Whether p110 β signaling occurs, at least partially, from the early endosome is still untested, and could suggest a role for Rab5 in localization of p110 β to allow and enhance its signaling from specific compartment or allow for a kinase-independent scaffolding role at the endosome limited to or extending beyond vps34.

Concluding remarks

The recent emergence of p110 β as a major player in development and tumorigenesis [59, 60] has spurred research into this catalytic isoform of PI3Ks. Understanding the regulation of the different class I PI3Ks is crucial for proper targeting of this pathway in disease conditions, particularly in PI3K-driven cancers. The frequency of activation of the PI3K pathway in tumors makes it an attractive target for therapeutics, however this has proven more complicated than anticipated. While p110 α is the most commonly mutated isoform in a variety of tumors, studies are still ongoing on the efficacy of isoform-specific inhibitors vs pan-PI3K inhibitors [104], although mutation-specific inhibitors could provide a valuable approach [105]. In fact, isoform-specific inhibitors, while useful tools for *in vitro* studies, have not translated to beneficial therapeutics for malignancies and disease. Several ATP-competitive inhibitors of p110 β have been generated and tested for their effects on p110 β -dependent processes such as PTEN-null tumor growth and platelet activation [62, 106–109], but their efficacy in the clinic has not been tested. With respect to p110 β , the targeting of different interactions may be useful and has been recently discussed [84], and the major target is blocking the interaction with G $\beta\gamma$ subunits which is the major activating mechanism for p110 β and regulates both kinase-dependent and -independent functions of p110 β such as membrane targeting [37, 110]. With respect to PI3K isoform-specific inhibitors in use, apart from a p110 δ -specific inhibitor, known as GS-1101 or CAL-101, which is beneficial in certain B-cell malignancies [111–113], they are in various stages of clinical trials, but redundancy of expression and functions between the different isoforms decreases their significance. The redundancy in signaling, seen at least in part due to the ubiquitous expression of p110 α and p110 β , suggests that dual inhibition of these isoforms may be beneficial to prevent compensation, and may even allow the use of lower doses of the

individual isoform-specific inhibitors in combinations to decrease negative side effects and increase efficacy in targeting the tumor [104]. The most clinically significant inhibitors are pan-PI3K inhibitors or those targeting multiple class I isoforms, or even dual PI3K/mTOR inhibitors [104, 114, 115]. Ongoing clinical trials focusing on isoform-specific as well as multi-isoform and pan-PI3K inhibitors will provide insight into the benefits of targeting each isoform or a combinatorial approach, and should yield benefits for therapeutics as well as understanding the interplay between the different isoforms.

The surge of data on p110 β has provided intriguing insights into a unique class I PI3K isoform that is distinct in its regulation and interactions from the other catalytic isoforms. These interactions are essential for understanding the function of p110 β in various physiological and cellular processes, as well as in tumors and other diseases. The careful characterization of p110 β interaction interfaces and identification of unique point mutations that block one function but not another will allow careful studies into p110 β functions and dissection of its role in different processes. Seeing as this isoform is ubiquitous and knockout shows such an early embryonic lethality [45], the roles of this PI3K isoform as well as the importance of different functions and interactions need to be explored in a wider range of tissues. For instance, the role of p110 β and its interactions in embryonic and adult stem cells needs to be further explored [116, 117], as well as its function in energy homeostasis and nutrient signaling and responses [118], in particular seeing its impact on autophagy and vps34 activity and signaling [40, 101], and even in male fertility [61]. Furthermore, the individual and distinct interaction surfaces on p110 β may be useful for drug design and targeting specific functions of p110 β without altering others, thereby minimizing potential side effects. Importantly, while these interactions have been mainly described individually, there is a need to address the interplay between these p110 β -interacting proteins and how they are coordinated relative to one another in order to modulate p110 β functions. Deciphering the complexity of kinase-dependent and -independent functions of p110 β mediated by its various interacting partners will yield valuable insight into the roles of this PI3K isoform in physiology and disease.

Acknowledgements

The work is performed in Dr. Melanie H. Cobb's lab at UTSW, and is funded by NIH grant R01 GM053032 (MHC). Hashem A. Dbouk is further supported by an American Heart Association postdoctoral fellowship.

References

1. Balla T. Phosphoinositides: tiny lipids with giant impact on cell regulation. *Physiol Rev.* 2013; 93(3):1019–1137. [PubMed: 23899561]
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat Rev Genet.* 2006; 7(8):606–619. [PubMed: 16847462]
3. Vanhaesebroeck B, et al. The emerging mechanisms of isoform-specific PI3K signalling. *Nat Rev Mol Cell Biol.* 2010; 11(5):329–341. [PubMed: 20379207]
4. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. *Nat Rev Mol Cell Biol.* 2012; 13(3):195–203. [PubMed: 22358332]
5. Geering B, et al. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. *Proc Natl Acad Sci U S A.* 2007; 104(19):7809–7814. [PubMed: 17470792]

6. Fruman DA. Regulatory subunits of class IA PI3K. *Curr Top Microbiol Immunol*. 2010; 346:225–244. [PubMed: 20563711]
7. Brock C, et al. Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma. *J Cell Biol*. 2003; 160(1):89–99. [PubMed: 12507995]
8. Kurig B, et al. Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110gamma. *Proc Natl Acad Sci U S A*. 2009; 106(48):20312–20317. [PubMed: 19906996]
9. Shymanets A, et al. The p101 subunit of PI3Kgamma restores activation by Gbeta mutants deficient in stimulating p110gamma. *Biochem J*. 2012; 441(3):851–858. [PubMed: 22054284]
10. Franke TF, et al. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. *Science*. 1997; 275(5300):665–668. [PubMed: 9005852]
11. Frech M, et al. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. *J Biol Chem*. 1997; 272(13):8474–8481. [PubMed: 9079675]
12. Bellacosa A, et al. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. *Science*. 1991; 254(5029):274–277. [PubMed: 1833819]
13. Coffey PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. *Eur J Biochem*. 1991; 201(2):475–481. [PubMed: 1718748]
14. Fayard E, et al. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. *Curr Top Microbiol Immunol*. 2010; 346:31–56. [PubMed: 20517722]
15. Alessi DR, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. *Curr Biol*. 1997; 7(4):261–269. [PubMed: 9094314]
16. Sarbassov DD, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science*. 2005; 307(5712):1098–1101. [PubMed: 15718470]
17. Alessi DR, et al. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. *FEBS Lett*. 1996; 399(3):333–338. [PubMed: 8985174]
18. Inoki K, et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. *Genes Dev*. 2003; 17(15):1829–1834. [PubMed: 12869586]
19. Manning BD, et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberlin as a target of the phosphoinositide 3-kinase/akt pathway. *Mol Cell*. 2002; 10(1):151–162. [PubMed: 12150915]
20. Tee AR, et al. Tuberous sclerosis complex gene products, Tuberlin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. *Curr Biol*. 2003; 13(15):1259–1268. [PubMed: 12906785]
21. Sancak Y, et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. *Science*. 2008; 320(5882):1496–1501. [PubMed: 18497260]
22. Hay N, Sonenberg N. Upstream and downstream of mTOR. *Genes Dev*. 2004; 18(16):1926–1945. [PubMed: 15314020]
23. Cross DA, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature*. 1995; 378(6559):785–789. [PubMed: 8524413]
24. Kane S, et al. A method to identify serine kinase substrates. Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. *J Biol Chem*. 2002; 277(25):22115–22118. [PubMed: 11994271]
25. Sano H, et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. *J Biol Chem*. 2003; 278(17):14599–14602. [PubMed: 12637568]
26. Datta SR, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell*. 1997; 91(2):231–241. [PubMed: 9346240]
27. Brunet A, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell*. 1999; 96(6):857–868. [PubMed: 10102273]
28. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. *Biochim Biophys Acta*. 2011; 1813(11):1938–1945. [PubMed: 21708191]

29. Ozes ON, et al. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. *Nature*. 1999; 401(6748):82–85. [PubMed: 10485710]
30. Pan ZK, et al. Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappaB activation in cultured human epithelial cells. *J Biol Chem*. 1999; 274(15):9918–9922. [PubMed: 10187765]
31. Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. *Mol Cell Biol*. 1999; 19(7):4798–4805. [PubMed: 10373529]
32. Castellano E, Downward J. RAS Interaction with PI3K: More Than Just Another Effector Pathway. *Genes Cancer*. 2011; 2(3):261–274. [PubMed: 21779497]
33. Kurosu H, et al. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110beta is synergistically activated by the betagamma subunits of G proteins and phosphotyrosyl peptide. *J Biol Chem*. 1997; 272(39):24252–24256. [PubMed: 9305878]
34. Maier U, Babich A, Nurnberg B. Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. *J Biol Chem*. 1999; 274(41):29311–29317. [PubMed: 10506190]
35. Murga C, Fukuhara S, Gutkind JS. A novel role for phosphatidylinositol 3-kinase beta in signaling from G protein-coupled receptors to Akt. *J Biol Chem*. 2000; 275(16):12069–12073. [PubMed: 10766839]
36. Guillermet-Guibert J, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. *Proc Natl Acad Sci U S A*. 2008; 105(24):8292–8297. [PubMed: 18544649]
37. Dbouk HA, et al. G protein-coupled receptor-mediated activation of p110beta by Gbetagamma is required for cellular transformation and invasiveness. *Sci Signal*. 2012; 5(253):ra89. [PubMed: 23211529]
38. Schmid MC, et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. *Cancer Cell*. 2011; 19(6):715–727. [PubMed: 21665146]
39. Kurosu H, Katada T. Association of phosphatidylinositol 3-kinase composed of p110beta-catalytic and p85-regulatory subunits with the small GTPase Rab5. *J Biochem*. 2001; 130(1):73–78. [PubMed: 11432782]
40. Dou Z, et al. Class IA PI3K p110beta subunit promotes autophagy through Rab5 small GTPase in response to growth factor limitation. *Mol Cell*. 2013; 50(1):29–42. [PubMed: 23434372]
41. Fritsch R, et al. RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms. *Cell*. 2013; 153(5):1050–1063. [PubMed: 23706742]
42. Bi L, et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. *J Biol Chem*. 1999; 274(16):10963–10968. [PubMed: 10196176]
43. Hirsch E, et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. *Science*. 2000; 287(5455):1049–1053. [PubMed: 10669418]
44. Okkenhaug K, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. *Science*. 2002; 297(5583):1031–1034. [PubMed: 12130661]
45. Bi L, et al. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. *Mamm Genome*. 2002; 13(3):169–172. [PubMed: 11919689]
46. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. *Oncogene*. 2008; 27(41):5497–5510. [PubMed: 18794884]
47. Jaiswal BS, et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. *Cancer Cell*. 2009; 16(6):463–474. [PubMed: 19962665]
48. Miled N, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. *Science*. 2007; 317(5835):239–242. [PubMed: 17626883]
49. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. *Cell Cycle*. 2004; 3(10):1221–1224. [PubMed: 15467468]
50. Simpson L, Parsons R. PTEN: life as a tumor suppressor. *Exp Cell Res*. 2001; 264(1):29–41. [PubMed: 11237521]

51. Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. *Trends Cell Biol.* 1999; 9(4):125–128. [PubMed: 10203785]
52. Angulo I, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. *Science.* 2013; 342(6160):866–871. [PubMed: 24136356]
53. Dbouk HA, et al. Characterization of a tumor-associated activating mutation of the p110beta PI 3-kinase. *PLoS One.* 2013; 8(5):e63833. [PubMed: 23734178]
54. Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. *Oncogene.* 2000; 19(44):5083–5090. [PubMed: 11042696]
55. Knobbe CB, Reifemberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. *Brain Pathol.* 2003; 13(4):507–518. [PubMed: 14655756]
56. Kang S, et al. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. *Proc Natl Acad Sci U S A.* 2006; 103(5):1289–1294. [PubMed: 16432180]
57. Wee S, et al. PTEN-deficient cancers depend on PIK3CB. *Proc Natl Acad Sci U S A.* 2008; 105(35):13057–13062. [PubMed: 18755892]
58. Berenjeno IM, et al. Both p110alpha and p110beta isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. *Biochem J.* 2012; 442(1):151–159. [PubMed: 22150431]
59. Ciraolo E, et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. *Sci Signal.* 2008; 1(36):ra3. [PubMed: 18780892]
60. Jia S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. *Nature.* 2008; 454(7205):776–779. [PubMed: 18594509]
61. Ciraolo E, et al. Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. *Molecular Biology of the Cell.* 2010; 21(5):704–711. [PubMed: 20053680]
62. Jackson SP, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. *Nat Med.* 2005; 11(5):507–514. [PubMed: 15834429]
63. Gratacap MP, et al. Regulation and roles of PI3Kbeta, a major actor in platelet signaling and functions. *Adv Enzyme Regul.* 2011; 51(1):106–116. [PubMed: 21035500]
64. Gross C, et al. Increased Expression of the PI3K Enhancer PIKE Mediates Deficits in Synaptic Plasticity and Behavior in Fragile X Syndrome. *Cell Rep.* 2015
65. Gross C, et al. Selective Role of the Catalytic PI3K Subunit p110beta in Impaired Higher Order Cognition in Fragile X Syndrome. *Cell Rep.* 2015
66. Hiles ID, et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. *Cell.* 1992; 70(3):419–429. [PubMed: 1322797]
67. Hu P, et al. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. *Mol Cell Biol.* 1993; 13(12):7677–7688. [PubMed: 8246984]
68. Yu J, et al. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. *Mol Cell Biol.* 1998; 18(3):1379–1387. [PubMed: 9488453]
69. Wu H, et al. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. *Proc Natl Acad Sci U S A.* 2009; 106(48):20258–20263. [PubMed: 19915146]
70. Yu J, Wjasow C, Backer JM. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. *J Biol Chem.* 1998; 273(46):30199–30203. [PubMed: 9804776]
71. Songyang Z, et al. SH2 domains recognize specific phosphopeptide sequences. *Cell.* 1993; 72(5):767–778. [PubMed: 7680959]
72. Huang CH, et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. *Science.* 2007; 318(5857):1744–1748. [PubMed: 18079394]

73. Mandelker D, et al. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. *Proc Natl Acad Sci U S A*. 2009; 106(40):16996–17001. [PubMed: 19805105]
74. Wu H, Yan Y, Backer JM. Regulation of class IA PI3Ks. *Biochem Soc Trans*. 2007; 35(Pt 2):242–244. [PubMed: 17371249]
75. Backer JM. The regulation of class IA PI 3-kinases by inter-subunit interactions. *Curr Top Microbiol Immunol*. 2010; 346:87–114. [PubMed: 20544340]
76. Sun M, et al. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. *Proc Natl Acad Sci U S A*. 2010; 107(35):15547–15552. [PubMed: 20713702]
77. Dbouk HA, et al. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. *Proc Natl Acad Sci U S A*. 2010; 107(46):19897–19902. [PubMed: 21030680]
78. Dbouk HA, Backer JM. A beta version of life: p110beta takes center stage. *Oncotarget*. 2010; 1(8):729–733. [PubMed: 21321382]
79. Burke JE, Williams RL. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). *Adv Biol Regul*. 2012
80. Jiang X, et al. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. *J Biol Chem*. 2010; 285(20):14980–14989. [PubMed: 20231295]
81. Rabinovsky R, et al. p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. *Mol Cell Biol*. 2009; 29(19):5377–5388. [PubMed: 19635806]
82. Zhang X, et al. Structure of lipid kinase p110beta/p85beta elucidates an unusual SH2-domain-mediated inhibitory mechanism. *Mol Cell*. 2011; 41(5):567–578. [PubMed: 21362552]
83. Vogt PK. PI3K p110beta: more tightly controlled or constitutively active? *Mol Cell*. 2011; 41(5):499–501. [PubMed: 21362546]
84. Dbouk HA, Backer JM. Novel approaches to inhibitor design for the p110beta phosphoinositide 3-kinase. *Trends Pharmacol Sci*. 2013; 34(3):149–153. [PubMed: 23411347]
85. Chantry D, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. *J Biol Chem*. 1997; 272(31):19236–19241. [PubMed: 9235916]
86. Kodaki T, et al. The activation of phosphatidylinositol 3-kinase by Ras. *Curr Biol*. 1994; 4(9):798–806. [PubMed: 7820549]
87. Pacold ME, et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. *Cell*. 2000; 103(6):931–943. [PubMed: 11136978]
88. Rodriguez-Viciana P, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. *Nature*. 1994; 370(6490):527–532. [PubMed: 8052307]
89. Rodriguez-Viciana P, et al. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. *EMBO J*. 1996; 15(10):2442–2451. [PubMed: 8665852]
90. Rubio I, et al. Interaction of Ras with phosphoinositide 3-kinase gamma. *Biochem J*. 1997; 326(Pt 3):891–895. [PubMed: 9307042]
91. Xu X, Jin T. A shortcut from GPCR signaling to Rac-mediated actin cytoskeleton through an ELMO/DOCK complex. *Small GTPases*. 2012; 3(3):183–185. [PubMed: 22647486]
92. Fritsch R, Downward J. SnapShot: Class I PI3K isoform signaling. *Cell*. 2013; 154(4):940–940.e1. [PubMed: 23953121]
93. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. *Nat Rev Cancer*. 2007; 7(2):79–94. [PubMed: 17251915]
94. Montaner S, et al. Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases. *Annu Rev Pharmacol Toxicol*. 2013; 53:331–354. [PubMed: 23092247]
95. O'Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. *Curr Opin Cell Biol*. 2014; 27C:126–135. [PubMed: 24508914]

96. Vadas O, et al. Molecular determinants of PI3Kgamma-mediated activation downstream of G-protein-coupled receptors (GPCRs). *Proc Natl Acad Sci U S A*. 2013; 110(47):18862–18867. [PubMed: 24190998]
97. Christoforidis S, et al. Phosphatidylinositol-3-OH kinases are Rab5 effectors. *Nat Cell Biol*. 1999; 1(4):249–252. [PubMed: 10559924]
98. Salamon RS, et al. Identification of the Rab5 Binding Site in p110beta: Assays for PI3Kbeta Binding to Rab5. *Methods Mol Biol*. 2015; 1298:271–281. [PubMed: 25800850]
99. Bucci C, et al. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. *Cell*. 1992; 70(5):715–728. [PubMed: 1516130]
100. Murray JT, et al. Role of Rab5 in the recruitment of hVps34/p150 to the early endosome. *Traffic*. 2002; 3(6):416–427. [PubMed: 12010460]
101. Dou Z, et al. The class IA phosphatidylinositol 3-kinase p110-beta subunit is a positive regulator of autophagy. *J Cell Biol*. 2010; 191(4):827–843. [PubMed: 21059846]
102. Chamberlain MD, et al. The p85alpha subunit of phosphatidylinositol 3'-kinase binds to and stimulates the GTPase activity of Rab proteins. *J Biol Chem*. 2004; 279(47):48607–48614. [PubMed: 15377662]
103. Garcia-Regalado A, et al. G protein-coupled receptor-promoted trafficking of Gbeta1gamma2 leads to AKT activation at endosomes via a mechanism mediated by Gbeta1gamma2-Rab11a interaction. *Mol Biol Cell*. 2008; 19(10):4188–4200. [PubMed: 18701709]
104. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. *Nat Rev Cancer*. 2015; 15(1):7–24. [PubMed: 25533673]
105. Hao Y, et al. Gain of interaction with IRS1 by p110alpha-helical domain mutants is crucial for their oncogenic functions. *Cancer Cell*. 2013; 23(5):583–593. [PubMed: 23643389]
106. Ni J, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent. *Cancer Discov*. 2012; 2(5):425–433. [PubMed: 22588880]
107. Barlaam B, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kbeta and PI3Kdelta for the treatment of PTEN-deficient cancers. *J Med Chem*. 2015; 58(2):943–962. [PubMed: 25514658]
108. Hancox U, et al. Inhibition of PI3Kbeta signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. *Mol Cancer Ther*. 2015; 14(1):48–58. [PubMed: 25398829]
109. Nylander S, et al. Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. *J Thromb Haemost*. 2012; 10(10):2127–2136. [PubMed: 22906130]
110. Dbouk HA, et al. PI3Kbeta downstream of GPCRs - crucial partners in oncogenesis. *Oncotarget*. 2012; 3(12):1485–1486. [PubMed: 23328076]
111. Fiorcari S, et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. *PLoS One*. 2013; 8(12):e83830. [PubMed: 24376763]
112. Fruman DA, Rommel C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. *Cancer Discov*. 2011; 1(7):562–572. [PubMed: 22586681]
113. Macias-Perez IM, Flinn IW. GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia. *Curr Hematol Malig Rep*. 2013; 8(1):22–27. [PubMed: 23114654]
114. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. *Nat Rev Drug Discov*. 2014; 13(2):140–156. [PubMed: 24481312]
115. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer*. 2009; 9(8):550–562. [PubMed: 19629070]
116. Kingham E, Welham M. Distinct roles for isoforms of the catalytic subunit of class-IA PI3K in the regulation of behaviour of murine embryonic stem cells. *J Cell Sci*. 2009; 122(Pt 13):2311–2321. [PubMed: 19509054]
117. Moir LM, et al. Phosphatidylinositol 3-kinase isoform-specific effects in airway mesenchymal cell function. *J Pharmacol Exp Ther*. 2011; 337(2):557–566. [PubMed: 21349933]

118. Al-Qassab H, et al. Dominant role of the p110beta isoform of PI3K over p110alpha in energy homeostasis regulation by POMC and AgRP neurons. *Cell Metab.* 2009; 10(5):343–354. [PubMed: 19883613]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1. Domain structure of p110β and regions of interactions

The p110β catalytic subunit consists of 5 domains: Adaptor-binding domain (ABD), Ras-binding domain (RBD), C2, helical and kinase domains. p110β can interact with p85 through its ABD, C2, helical and kinase domains, although the C2-iSH2 contact is diminished or absent (dashed line) when compared to other class IA catalytic subunits. p110β can also interact with Rac and cdc42 through the RBD domain, with Gβγ subunits binding p110β at the linker region between the C2 and helical domains, and with Rab5 at the helical domain. These different interactions mediate the many functions of p110β in maintaining basal PI(3,4,5)P₃ levels, signaling from receptors, autophagy, and are deregulated in tumors and disease conditions.

Table 1

PI3K classes, subunits, substrates, and products.

Class	Catalytic Subunit(s)	Regulatory Subunit(s)	Substrate	Product
I A	p110 α , β , δ	p85 α , p55 α , p50 α p85 β , p55 γ	PI(4,5)P ₂	PI(3,4,5)P ₃
I B	p110 γ	p101/p87	PI(4,5)P ₂	PI(3,4,5)P ₃
II	PIK3C2 α , β , γ	-	PI, PI(4)P	PI(3)P, PI(3,4)P ₂
III	vps34	vps15	PI	PI(3)P